Valion Bio, Inc. Common Stock (NASDAQ:VBIO – Get Free Report) and Xilio Therapeutics (NASDAQ:XLO – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, valuation, institutional ownership, profitability and analyst recommendations.
Earnings & Valuation
This table compares Valion Bio, Inc. Common Stock and Xilio Therapeutics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Valion Bio, Inc. Common Stock | $780,000.00 | 0.57 | -$8.88 million | ($159.25) | -0.00 |
| Xilio Therapeutics | $43.77 million | 1.30 | -$35.04 million | ($1.64) | -5.26 |
Valion Bio, Inc. Common Stock has higher earnings, but lower revenue than Xilio Therapeutics. Xilio Therapeutics is trading at a lower price-to-earnings ratio than Valion Bio, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Valion Bio, Inc. Common Stock and Xilio Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Valion Bio, Inc. Common Stock | N/A | -193.17% | -67.10% |
| Xilio Therapeutics | -34.06% | -71.99% | -20.43% |
Insider and Institutional Ownership
4.3% of Valion Bio, Inc. Common Stock shares are held by institutional investors. Comparatively, 54.3% of Xilio Therapeutics shares are held by institutional investors. 0.9% of Valion Bio, Inc. Common Stock shares are held by insiders. Comparatively, 7.4% of Xilio Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Volatility & Risk
Valion Bio, Inc. Common Stock has a beta of 1.91, indicating that its share price is 91% more volatile than the S&P 500. Comparatively, Xilio Therapeutics has a beta of -0.13, indicating that its share price is 113% less volatile than the S&P 500.
Analyst Ratings
This is a summary of current ratings and target prices for Valion Bio, Inc. Common Stock and Xilio Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Valion Bio, Inc. Common Stock | 1 | 0 | 0 | 0 | 1.00 |
| Xilio Therapeutics | 1 | 1 | 1 | 0 | 2.00 |
Xilio Therapeutics has a consensus price target of $16.00, suggesting a potential upside of 85.61%. Given Xilio Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Xilio Therapeutics is more favorable than Valion Bio, Inc. Common Stock.
Summary
Xilio Therapeutics beats Valion Bio, Inc. Common Stock on 10 of the 13 factors compared between the two stocks.
About Valion Bio, Inc. Common Stock
Tivic Health Systems Inc. operates as a health tech company, focuses on developing and commercializing bioelectronic medicine. Its primary product is ClearUP, a bioelectronic medicine for the treatment of sinus and nasal inflammation. The company sells its products on direct-to-consumer channel through its own websites; and platforms, such as Amazon.com and Walmart.com, as well as to U.S. online retailers, such as BestBuy and FSAStore and through distributors. Tivic Health Systems, Inc. was incorporated in 2016 and is headquartered in Hayward, California.
About Xilio Therapeutics
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company’s checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.
Receive News & Ratings for Valion Bio Inc. Common Stock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valion Bio Inc. Common Stock and related companies with MarketBeat.com's FREE daily email newsletter.
